Memo Therapeutics AG announced that the U.S. Food and Drug Administration has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus infection commonly seen in renal transplant patients.
Memo Therapeutics AG announced that the U.S. Food and Drug Administration has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus infection commonly seen in renal transplant patients.